Ra Capital Management, L.P. Purchases 213,099 Shares of Climb Bio (NASDAQ:CLYM) Stock

Climb Bio, Inc. (NASDAQ:CLYM) Director Ra Capital Management, L.P. acquired 213,099 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was bought at an average cost of $2.18 per share, for a total transaction of $464,555.82. Following the completion of the transaction, the director directly owned 3,294,856 shares of the company’s stock, valued at $7,182,786.08. This trade represents a 6.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, December 12th, Ra Capital Management, L.P. acquired 101,462 shares of Climb Bio stock. The shares were bought at an average price of $2.86 per share, for a total transaction of $290,181.32.

Climb Bio Stock Performance

Shares of CLYM stock traded up $0.81 during trading hours on Monday, reaching $3.81. The company had a trading volume of 22,503,757 shares, compared to its average volume of 795,270. The stock’s fifty day simple moving average is $1.97 and its 200 day simple moving average is $1.80. The company has a market capitalization of $259.77 million, a P/E ratio of -5.01 and a beta of -0.06. Climb Bio, Inc. has a twelve month low of $1.05 and a twelve month high of $4.82.

Climb Bio (NASDAQ:CLYM) last posted its earnings results on Thursday, November 6th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). As a group, equities analysts expect that Climb Bio, Inc. will post -1.57 earnings per share for the current year.

Hedge Funds Weigh In On Climb Bio

A number of large investors have recently made changes to their positions in the business. Peapod Lane Capital LLC increased its stake in Climb Bio by 1.1% in the 3rd quarter. Peapod Lane Capital LLC now owns 561,866 shares of the company’s stock valued at $1,129,000 after buying an additional 6,199 shares during the period. ADAR1 Capital Management LLC raised its holdings in shares of Climb Bio by 11.9% during the 3rd quarter. ADAR1 Capital Management LLC now owns 133,530 shares of the company’s stock valued at $268,000 after purchasing an additional 14,210 shares in the last quarter. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Climb Bio in the third quarter worth about $29,000. AQR Capital Management LLC bought a new stake in shares of Climb Bio during the 1st quarter worth about $27,000. Finally, UBS Group AG increased its holdings in shares of Climb Bio by 6.0% during the 3rd quarter. UBS Group AG now owns 405,404 shares of the company’s stock valued at $815,000 after acquiring an additional 22,922 shares during the last quarter. Institutional investors and hedge funds own 69.76% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of Climb Bio in a report on Thursday, October 16th. William Blair assumed coverage on shares of Climb Bio in a research report on Thursday, October 16th. They issued an “outperform” rating for the company. Wall Street Zen lowered Climb Bio from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. HC Wainwright started coverage on Climb Bio in a research note on Monday, October 13th. They issued a “buy” rating and a $9.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.